secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuraxis, INC (NRXS)
CIK:        0001933567
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001493152-25-001323
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M
----------------------------------------------------------------

- Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).
- Cash balance as of Dec 31, 2024 was ~$3.7 million.
- Insurance coverage expanded to ~45M lives, up from 4M a year ago.
- FDA 510(k) clearance for IB-Stim expanded to ages 8-21; new CPT code for PENFS.
- Commercialization of FDA-approved Rectal Expulsion Device (RED) begins Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933567/000149315225001323/0001493152-25-001323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933567/000149315225001323/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer